TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19021624

Group type: EXPERIMENTAL
Intervention: PNB combined with Antrolin cream (group B)
Number of subjects: 200

Group type: COMPARATOR
Intervention: PNB alone (group A)
Number of subjects: 200
Study: 18210825

Group type: EXPERIMENTAL
Intervention: Prednisone protocol plus extended transsternal thymectomy (ETTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone protocol alone
Number of subjects: 0
Study: 15870631

Group type: EXPERIMENTAL
Intervention: Prior heavy exercise (three 73-s efforts at 90% CP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Prior severe exercise (three 60-s efforts at 110% CP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Prior heavy exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Prior severe exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control trial (CON)
Number of subjects: 11
Study: 11833753

Group type: EXPERIMENTAL
Intervention: Immune-enhancing oral formula (Advera)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Standard oral formula (Ensure Plus)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 9933772

Group type: EXPERIMENTAL
Intervention: Nidek EAS‐1000 retroillumination image analysis
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard pupil size analyses
Number of subjects: 450

Group type: COMPARATOR
Intervention: Maximal pupil size analyses
Number of subjects: 450
Study: 8583780

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination of low doses of HCTZ and furosemide (FU)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Furosemide (FU)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (patients with advanced renal failure)
Number of subjects: 25
Study: 2182314

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 44000

Group type: EXPERIMENTAL
Intervention: Combined modality adjuvant therapy
Number of subjects: 44000
Study: 342639

Group type: EXPERIMENTAL
Intervention: High-titer immune serum globulin (3-ml injections, two doses, four months apart)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Low-titer immune serum globulin (3-ml injections, two doses, four months apart)
Number of subjects: 566
Study: 29915021

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Insulin glulisine
Number of subjects: 34
Study: 26291425

Group type: EXPERIMENTAL
Intervention: Valethamate bromide
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 23774314

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids (HDS; hydrocortisone, 100 mg, intravenously 3 times daily, followed by taper)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low-dose corticosteroids (LDS; intravenous hydrocortisone equivalent to presurgical oral dosing, followed by taper)
Number of subjects: 92
Study: 22583760

Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus 0.75 mg/kg followed by infusion during the procedure; n = 198)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH; 75 IU/kg; n = 203)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 401

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 401
Study: 20555368

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (As group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (Pl group)
Number of subjects: 16
Study: 18781872

Group type: EXPERIMENTAL
Intervention: ddI/3TC/EFV
Number of subjects: 369

Group type: COMPARATOR
Intervention: COM/EFV
Number of subjects: 369
Study: 15715270

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate-high-monounsaturated-fat (Glucerna)
Number of subjects: 104

Group type: COMPARATOR
Intervention: High-carbohydrate diet (Precitene Diabet)
Number of subjects: 104
Study: 12401122

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 2.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10546082

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 275
Study: 8678264

Group type: EXPERIMENTAL
Intervention: hyaluronidase 150 iu.ml‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: no hyaluronidase (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: hyaluronidase 50 iu.ml‐1
Number of subjects: 60
Study: 1690974

Group type: EXPERIMENTAL
Intervention: Albumin 5% (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hetastarch 6% (group 2)
Number of subjects: 40
Study: 550143

Group type: EXPERIMENTAL
Intervention: High sodium diet (200 mmols/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low sodium diet (40 mmols/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Saline infusion during low sodium diet
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dextrose and water infusion during low sodium diet
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Indomethacin or ibuprofen administration during saline and dextrose and water infusions
Number of subjects: 13
Study: 31395900

Group type: EXPERIMENTAL
Intervention: FOLFOX-4 or XELOX adjuvant chemotherapy for 6 months
Number of subjects: 512
Study: 27696750

Group type: EXPERIMENTAL
Intervention: Strengthening and Stretching for Rheumatoid Arthritis of the Hand (SARAH) exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26239323

Group type: EXPERIMENTAL
Intervention: Continuous infusion vancomycin (target random levels, 20‐30 mg/L)
Number of subjects: 130
Study: 24077095

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) 400 μg/10 μg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/S) 460 μg/42 μg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) 200 μg/10 μg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 21295941

Group type: EXPERIMENTAL
Intervention: Insall-Burstein II
Number of subjects: 84

Group type: COMPARATOR
Intervention: NexGen Legacy
Number of subjects: 84
Study: 19363973

Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT (bulk technique)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT (incremental technique)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + Filtek Supreme XT (bulk technique)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + Filtek Supreme XT (incremental technique)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + Ribbond (bulk technique)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + Ribbond (incremental technique)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + everStick NET (bulk technique)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + everStick NET (incremental technique)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ribbond fiber in composite
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: everStick NET fiber in composite
Number of subjects: 80
Study: 16571758

Group type: EXPERIMENTAL
Intervention: Rest condition with stimulation at 4x pain threshold (PT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Movement condition with stimulation at 4x pain threshold (PT)
Number of subjects: 10
Study: 12514457

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam
Number of subjects: 93

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 93
Study: 11057355

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ketotifen fumarate 0.05%
Number of subjects: 80
Study: 9065359

Group type: EXPERIMENTAL
Intervention: Rivermead Motor Assessment - Gross Function Section
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rivermead Motor Assessment - Arm Section
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rivermead Motor Assessment - Leg and Trunk Section
Number of subjects: 51
Study: 7998413

Group type: EXPERIMENTAL
Intervention: 1 ml HBIg at birth followed by hepatitis B immunization (20 micrograms) at 3, 4, 5 and 11 months (schedule E)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: HBIg at 3 months (schedule F)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Plasma vaccine (10 micrograms) according to schedule F (historic controls)
Number of subjects: 195
Study: 3376877

Group type: COMPARATOR
Intervention: Nitrogen dioxide (NO2) exposure at 0.0 ppm (control)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure at 0.3 ppm
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure at 0.6 ppm
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ambient air exposure (mean NO2 concentration 0.086 +/- 0.024 ppm)
Number of subjects: 59
Study: 30188231

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + chemotherapy (carboplatin/cisplatin + pemetrexed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + chemotherapy
Number of subjects: 0
Study: 25611941

Group type: EXPERIMENTAL
Intervention: Health education teachers
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: School nurses
Number of subjects: 1357

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 1357
Study: 23712757

Group type: EXPERIMENTAL
Intervention: Danoprevir 100 mg and Ritonavir 100 mg co-administered with Ciclosporin 100 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Danoprevir 100 mg and Ritonavir 100 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ciclosporin 100 mg
Number of subjects: 18
Study: 20810374

Group type: EXPERIMENTAL
Intervention: Risk-reducing mastectomy
Number of subjects: 2482

Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy
Number of subjects: 2482
Study: 18837608

Group type: EXPERIMENTAL
Intervention: Peer-identified KOL teachers and mental health providers (n = 12 KOLs and n = 21 providers)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Mental health provider consultation only (n = 54 teachers)
Number of subjects: 61
Study: 16820345

Group type: EXPERIMENTAL
Intervention: Magnesium potassium supplementation (magnesium, 70.8 mg/d; potassium, 217.2 mg/d) for four weeks
Number of subjects: 133

Group type: COMPARATOR
Intervention: Lacidipine (4 mg/d) as control
Number of subjects: 133
Study: 14524395

Group type: EXPERIMENTAL
Intervention: Oral ivermectin
Number of subjects: 0
Study: 11119328

Group type: EXPERIMENTAL
Intervention: Focal spraying with deltamethrin 5% SC at 25 mg a. i./m2 (PT group)
Number of subjects: 1541

Group type: EXPERIMENTAL
Intervention: Focal spraying with slow-release malathion 8.3% SR at 2g a. i./m2 (PL group)
Number of subjects: 1541

Group type: COMPARATOR
Intervention: Conventional spraying with deltamethrin indoors and in the peridomicile (PT group)
Number of subjects: 1541

Group type: COMPARATOR
Intervention: Conventional spraying with deltamethrin indoors and slow-release malathion in the peridomicile (PL group)
Number of subjects: 1541
Study: 8763182

Group type: EXPERIMENTAL
Intervention: Cefuroxime (30 mg/kg) at induction of anaesthesia
Number of subjects: 150

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 150
Study: 1707255

Group type: EXPERIMENTAL
Intervention: Esophageal intubation with an Atkinson tube (AT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Esophageal intubation followed by radiation therapy (AT/RT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Endoscopic laser therapy followed by irradiation (L/RT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: AT group
Number of subjects: 27

Group type: COMPARATOR
Intervention: L/RT group
Number of subjects: 27
Study: 6177981

Group type: EXPERIMENTAL
Intervention: Oral human gammaglobulin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31959601

Group type: EXPERIMENTAL
Intervention: 3D intervention (comprehensive 6‐monthly general practitioner consultations, supported by medication reviews and nurse appointments)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: 3D intervention
Number of subjects: 797

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 797
Study: 30137522

Group type: EXPERIMENTAL
Intervention: Curriculum regarding LGBT medical care concepts
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Survey and interview regarding LGBT curriculum at USU
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Published curriculum
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of faculty interviews
Number of subjects: 24
Study: 28948690

Group type: EXPERIMENTAL
Intervention: Smartphone-based support groups
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control condition (information)
Number of subjects: 203
Study: 26031828

Group type: EXPERIMENTAL
Intervention: Arg infusion (0.5 g/kg, 30 min)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: High-fat protein meals
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Daily Arg ingestion (10 g)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 23906999

Group type: EXPERIMENTAL
Intervention: Topiramate (100-300 mg/day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 106
Study: 20860717

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 2417

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 2417

Group type: COMPARATOR
Intervention: tolterodine ER 4 mg
Number of subjects: 2417

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2417

Group type: EXPERIMENTAL
Intervention: fesoterodine
Number of subjects: 2417

Group type: COMPARATOR
Intervention: tolterodine ER
Number of subjects: 2417
Study: 19555253

Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg/day
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg/day + Simvastatin 40 mg/day
Number of subjects: 241
Study: 17698761

Group type: EXPERIMENTAL
Intervention: Surgical placement of an implantable telescope prosthesis
Number of subjects: 0
Study: 15390343

Group type: EXPERIMENTAL
Intervention: Low dose alcohol (1.6 +/- 0.4 ml)
Number of subjects: 34

Group type: COMPARATOR
Intervention: High dose alcohol (3.4 +/- 0.9 ml)
Number of subjects: 34
Study: 11228295

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (two drops)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10197074

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 6 i.u. s.c. twice daily from 2 days before until 7 days after surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and Placebo
Number of subjects: 24
Study: 7815310

Group type: EXPERIMENTAL
Intervention: rec-hirudin, 0.1 mg/kg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rec-hirudin, 0.3 mg/kg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rec-hirudin, 0.5 mg/kg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rec-hirudin, 1 mg/kg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rec-hirudin (all doses)
Number of subjects: 77
Study: 2544829

Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intramuscular ACTH
Number of subjects: 61
Study: 31066313

Group type: EXPERIMENTAL
Intervention: Mentoring with mentors with visual impairment (N=25)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mentoring with mentors without visual impairment (N=26)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Care-as-usual (N=25)
Number of subjects: 76
Study: 30624555

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28702806

Group type: EXPERIMENTAL
Intervention: Nintedanib plus Docetaxel
Number of subjects: 0
Study: 25342652

Group type: EXPERIMENTAL
Intervention: Endovascular therapies (EVTs)
Number of subjects: 200
Study: 22982425

Group type: EXPERIMENTAL
Intervention: Urodynamic studies after office evaluation
Number of subjects: 294
Study: 21986208

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) with conditioning from common peroneal nerve (CPN) at CT intervals of 35 ms and 50-55 ms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the posterior tibial nerve (PTN) to activate H-reflexes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subthreshold TMS pulse with CPN stimulation at CT intervals of 40-45 ms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPN stimulation prior to dorsiflexion.
Number of subjects: 0
Study: 18687539

Group type: EXPERIMENTAL
Intervention: Tibolone (1.25 mg/day women's equivalent)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Soy + Tibolone (138 mg isoflavones/day women's equivalent)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Soy (52 g of soy protein containing 112 mg isoflavones)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (52 g of milk protein)
Number of subjects: 18
Study: 16822116

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) plus fluoxetine
Number of subjects: 108

Group type: COMPARATOR
Intervention: CBT plus placebo
Number of subjects: 108
Study: 12566778

Group type: EXPERIMENTAL
Intervention: PGE(1) gel administered in the ambulatory form (group 1)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PGE(1) gel administered in the labor room (group 2)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intravenously administered oxytocin (group 3)
Number of subjects: 89
Study: 10871006

Group type: EXPERIMENTAL
Intervention: Voxel size of 0.95 x 0.76 x 0.82 mm (group 2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Voxel size of 1.3 x 1.29 x 1.25 mm (group 1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Conventional resolution technique
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-resolution technique
Number of subjects: 44
Study: 9198048

Group type: EXPERIMENTAL
Intervention: High-efficiency haemodialysis (dialyser blood flow rate = 400 ml/min; dialysis time = 170.67 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard haemodialysis (dialyser blood flow rate = 200 ml/min; dialysis time = 240 min)
Number of subjects: 6
Study: 8475871

Group type: EXPERIMENTAL
Intervention: New York Heart Association class I patients
Number of subjects: 308

Group type: COMPARATOR
Intervention: New York Heart Association class II or III patients
Number of subjects: 308
Study: 2580678

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of amino acids (100 ml/hr 10%)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of fat (100 ml/hr 10%)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glucose (150 ml/hr 10%)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of higher glucose dose (100 ml 20% glucose as a bolus followed by 300 ml/hr 10%)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 31
Study: 30006299

Group type: EXPERIMENTAL
Intervention: Caprylidene
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27423055

Group type: EXPERIMENTAL
Intervention: Moderately intense glucose control
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 60
Study: 24332139

Group type: EXPERIMENTAL
Intervention: CVAR assessment by trained family physicians with an electronic CVAR calculator
Number of subjects: 1074

Group type: COMPARATOR
Intervention: General health check (Control)
Number of subjects: 1074
Study: 23095609

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection device
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional dissection
Number of subjects: 101
Study: 19422632

Group type: EXPERIMENTAL
Intervention: Telephone support and counselling 2 and 10 weeks after surgery
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional care and treatment (Control)
Number of subjects: 180
Study: 17660006

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate in alcohol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Iodine povacrylex in alcohol
Number of subjects: 36
Study: 16280002

Group type: EXPERIMENTAL
Intervention: DISKHALER dry powder inhaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: ROTAHALER dry powder inhaler
Number of subjects: 0
Study: 12212977

Group type: EXPERIMENTAL
Intervention: Unprotected group (no half-mask)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Half-mask group
Number of subjects: 33
Study: 10441861

Group type: EXPERIMENTAL
Intervention: Intravenous administration of trometamol salt of thioctic (alpha-lipoic) acid (Thioctacid 600) in 200 ml of physiological solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (physiological solution stained with 1% solution of riboflavin mononucleate)
Number of subjects: 40
Study: 7794850

Group type: EXPERIMENTAL
Intervention: 75 mg oestradiol implants
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (14 women)
Number of subjects: 32
Study: 2217893

Group type: EXPERIMENTAL
Intervention: Intramuscular P (group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intramuscular P and hCG (group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No support (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group C (intramuscular P and hCG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pregnant cycles
Number of subjects: 30
Study: 789186

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 200